Results: The A-LEN group produced the best rate pressure product when compared with the A-NEL or A-NEN group (P = 0.045, P = 0.011, respectively). In regard to pulmonary venous pressure, the A-LEN group was lower than the A-NEL or A-NEN group (P = 0.031, P = 0.006, respectively). Animals in the A-NEL and A-NEN groups rapidly developed pulmonary edema after infusion of epinephrine. The wet-to-dry ratio of the lungs in the A-LEN group was lower than that of the lungs in the A-NEL group (P = 0.024).The lung permeability index of the A-LEN group was lower than that of the A-NEL group (P = 0.011). In experiment B, concentrations of bupivacaine in cardiac tissue and plasma of the B-LEN group were lower than those of the B-NEL group (P = 0.001, P = 0.03, respectively).
Conclusions: Giving priority to the administration of a lipid emulsion before the administration of epinephrine can reduce lung injury in bupivacaine-induced cardiac depression in rats.
(Reg Anesth Pain Med 2016;41: 469-476) E pinephrine is a common drug for treating cardiac arrest because it facilitates patient recovery through its α-agonist activity (increasing diastolic pressure and coronary perfusion pressure). 1 A large number of studies have focused on the administration of lipid with epinephrine in bupivacaine-induced cardiac arrest. 2, 3 Recent work by Harvey et al 4 demonstrated that epinephrine was necessary for the return of spontaneous circulation in lipid-based resuscitation from local anesthetic-induced cardiac arrest. This finding is consistent with our previous work 5 in the isolated rat heart model of bupivacaine toxicity, where lipid emulsion combined with epinephrine produced superior coronary flows and rate pressure product (RPP) during resuscitation than did the lipid emulsion alone.
Unfortunately, epinephrine has adverse effects. For example, hypertension, tachycardia, myocyte injury, and pulmonary edema may occur during and after cardiopulmonary resuscitation. 6 McCaul et al 7 demonstrated that epinephrine increases mortality in the setting of brief cardiac arrest after asphyxia. This was associated with early transient left atrial hypertension accompanied by a dose-related reduction in left ventricular end-diastolic diameter. Results from Hiller's group 8 showed that epinephrine has a threshold effect (10 μg/kg) that impaired lipid resuscitation in a bupivacaine overdose as demonstrated by a significant acidosis and severe pulmonary edema.
Our previous study demonstrated that the timing of epinephrine administration affected the effectiveness of resuscitation in bupivacaine toxicity. 9 Therefore, we hypothesized that epinephrine administration increases pulmonary venous pressures (PVPs), thereby inducing lung injury in bupivacaine-induced cardiac depression. In this study, we report that administration of a lipid emulsion before epinephrine resulted in decreased PVPs and minimized lung injury. Our primary measurements were the wet weight-to-dry ratio of lung tissue and the lung permeability index (LPI; 30 minutes after bupivacaine injection). Secondary outcome measures were PVP, pulmonary arterial pressure (PAP), and bupivacaine concentration.
METHODS

Experimental Animals
Healthy male Sprague-Dawley rats, 7 to 8 weeks old, were purchased from Shanghai Slac Laboratory Animal Co, Ltd (Shanghai, China). The animals were housed in plastic cages (4 rats per cage) at the animal center of Wenzhou Medical University in a standard 12-hour reverse day-night cycle at an ambient temperature of 26°C. The animals had an ad libitum diet of stock laboratory nutrition (Beijing Keao-Xieli Feedstuff Co, Ltd, Beijing, China) and tap water. The rats were 8 to 10 weeks of age and weighed 300 to 400 g when they were entered into the study.
Anesthesia and Monitoring
The animals were fasted for 12 hours before the experiments with free access to water. All experiments commenced at or before 9 AM. On the day of the experiment, rats were anesthetized with an intraperitoneal injection of chloral hydrate (350 mg/kg) and placed supine on a heating pad that maintained body temperature at 36°C to 37°C. The airways were secured via tracheotomy and mechanically ventilated with 1% to 2% sevoflurane in 100% oxygen. A rodent volume-controlled ventilator (HX-300; TME Technology Co, Ltd, Chengdu, China) was used with a tidal volume of 8 mL/kg, a respiratory rate of 75 to 80 breaths/min, and an inspiratory-to-expiratory ratio of 2:3. Catheters were inserted into the right internal jugular vein, the left femoral vein, and femoral artery. All rats received a midline incision of the chest, and an 18°Teflon catheter (Becton Dickinson, Sandy, Utah) was advanced into the main pulmonary artery through the right ventricle for measurement of PAP. A polyethylene catheter was also placed into the pulmonary vein via the left atrium for measurement of PVP. All animals were allowed to stabilize for 15 minutes at 0.5% sevoflurane in 100% oxygen after completion of the invasive procedures. At which time baseline heart rate (HR), mean arterial pressure (MAP), and RPP were recorded.
Experiment A
Grouping of Animals and Experiment Protocol
At the end of the stabilization period, 15 mg/kg bupivacaine was infused at the rate of 2 mg·kg −1 ·min −1 , 10 for 7.5 minutes via the right femoral vein. The end of the bupivacaine infusion was designated as time 0 (RPP was 30% below baseline values). Animals (n = 8 for each group) were randomly assigned to receive 1 of 3 treatments according to the following regimens (each of which occurred over a 2-minute period).
(1) Lipid-epinephrine treatment (A-LEN group): a 30% Intralipid (Huarui Pharmaceuticals Co Ltd, Wuxi, China) was infused at the rate of 3.0 mL· kg −1 ·min −1 for 1 minute via the right femoral vein. This was followed by a rapid bolus of 10 μg/kg epinephrine delivered immediately after the lipid emulsion treatment. Then a normal saline infusion was administered at the rate of 3.0 mL·kg −1 ·min −1 for 1 minute during the second minute. (2) Epinephrine-lipid treatment (A-NEL group): a normal saline infusion was administered at the rate of 3.0 mL·kg −1 ·min −1 for 1 minute during the first minute. This was followed by a rapid bolus of 10 μg/kg epinephrine delivered immediately. Then a 30% intralipid was infused in the same fashion as in the A-LEN group during the second minute. (3) Epinephrine treatment (A-NEN group, serving as a control group): a normal saline infusion was administered at the rate of 3.0 mL·kg −1 ·min −1 for 1 minute during the first minute. This was followed by a rapid bolus of 10 μg/kg epinephrine delivered immediately. Then a normal saline infusion was administered at the rate of 3.0 mL·kg −1 ·min −1 for 1 minute during the second minute ( Fig. 1 ). The experiment was stopped after 30 minutes (the observation period). The experiments were not blinded. However, data were later collated and analyzed by personnel blinded to the treatment groups.
Data Acquisition
The HR, MAP, RPP, PVP, PAP, −dp/dt, +dp/dt were continuously recorded until the termination of the observation period. Blood samples were drawn for arterial blood gas analysis and serum lactate measurements at baseline and 30 minutes.
Wet-to-Dry Ratio of Lung Tissue (by Weight)
The second lobe of right rat lungs was harvested at 30 minutes, weighed, and then desiccated at 75°C for 24 hours. It was then reweighed to determine the wet-to-dry (W/D) ratio 11 and LPI.
Five milliliters of cold normal saline was injected into the left lung bronchus 3 times, gently aspirated, and collected as described previously. 12 The content of bronchoalveolar lavage fluid (BALF) collected was consistently greater than 12 mL. The BALF was centrifuged at 1000 revolutions/min at 4°C for 10 minutes. Bronchoalveolar lavage protein content was determined by the bicinchoninic acid assay, and absorbance read at 595 nm. The LPI is calculated as the BALF protein concentration divided by plasma total protein concentration. 13 
Histological Analyses of Lung Tissue
Histological examination of lung tissue was performed by a method previously described.
14 The third lobe of right rat lungs was removed rapidly. The lung was soaked in 10% formaldehyde solution for 24 hours and stained with hematoxylin-eosin. Sections were evaluated by light microscopy by a pathologist who was blinded to the groups. Gross examination was performed, and images were recorded with a digital camera.
Electron Microscopy Examination
Electron microscopy examination of lungs was performed by a method previously described. 15 The fourth lobe of the rats' right lung was prepared for electron microscopy in fixative (1% glutaraldehyde and 4% paraformaldehyde in 0.1 M phosphate buffer).
Experiment B
Grouping of Animals and Experiment Protocol
Two groups of animals (n = 8 for each group) were randomized (by blind number drawing) to 1 of 2 treatment groups: lipid-epinephrine (B-LEN) or epinephrine-lipid (B-NEL) treatment groups.
The B experimental model and protocol were same as those used for the A-LEN and A-NEL groups in experiment A. At the end of 2 minutes, all animals were killed. The hearts and blood were harvested and stored at −80 C until analysis was performed.
Data Acquisition
High-performance liquid chromatography was used to measure the bupivacaine content. 16 The studies were not blinded, but the data were analyzed in a blinded fashion.
Statistical Analysis
The power analysis was based on results of preliminary experiments comparing PVP at 3 minutes among various treatment groups and yielded a sample size of n = 6 for each group; power was set at 0.8, significance criterion was set at 0.05, effect size was estimated as 2, and sigma at 0.9. Animal losses were taken into account, so a sample size of 8 was chosen for each group (PASS 11 software, NCSS, Kaysville, UT). All data were analyzed using SPSS for Microsoft Windows (version 16.0; SPSS, Chicago, Illinois). Baseline parameters, wet-to-dry lung weight ratios, and LPI were analyzed by 1-way analysis of variance. When statistical significance was achieved, P < 0.05, post hoc multiple comparisons were made using least significant difference. Continuous hemodynamic variables in animals surviving at 30 minutes were compared across time by 2-way repeatedmeasures analysis of variance.
RESULTS
Experiment A
Characteristics of Study Subjects
Baseline values for key hemodynamic and metabolic parameters were compared for the 3 groups (Table 1 ). There were no differences among mean baseline values for HR, MAP, RPP, −dp/dt, +dp/dt, PAP, and PVP arterial blood gas measurements.
Cardiovascular Function Measurements
Rate pressure product was less than 30% of the basic values at the end of the bupivacaine infusion. The hemodynamic parameters of HR ( Fig. 2A) , RPP (Fig. 2B) , and MAP ( 
Pulmonary Vascular Pressure Measurements
Pulmonary Vein Pressure. Figure 3B demonstrates the changes of PVP during the experimental observation period. The PVP of A-LEN was significantly lower than A-NEL and A-NEN groups (F = 6.57 P = 0.006 A-LEN vs A-NEL group, P = 0.007; A-LEN vs A-NEN group, P = 0.004; A-NEL vs A-NEN group, P = 0.817). Epinephrine administration increased the PVP rapidly, reaching its maximal value at about 1 minute. The values returned to baseline by 3 minutes (Fig. 3A) (F = 4.99 P = 0.019 A-LEN vs A-NEL, P = 0.004; A-LEN vs A-NEN, P = 0.003; A-NEL vs A-NEN group, P = 0.938).
Pulmonary Arterial Pressure. There were no differences in the PAP among 3 groups in the 3-minute period after epinephrine administration (PAP0-240 s: F = 1.335 P = 0.288; A-LEN vs A-NEL group, P = 0.231; A-LEN vs A-NEN group, P = 0.141; A-NEL vs A-NEN group, P = 0.765) (Fig. 3C) , or during the entire observational period (PAP0-30 min: F = 1.237 P = 0.314; A-LEN vs A-NEL group, P = 0.139; A-LEN vs A-NEN group, P = 0.32; A-NEL vs A-NEN group, P = 0.607) (Fig. 3D) .
Pulmonary Effects. The degree of pulmonary edema was assessed by calculating the W/D ratio and by the LPI. As shown in Figure 4A , administering only epinephrine or infusing lipid after epinephrine caused a significant increase in the W/D ratio (7.5 ± 0.64;7.41 ± 0.44). These results demonstrated the advantage (priority of effect) of initially infusing Intralipid (6.69 ± 0.74) (A-LEN vs A-NEL, P = 0.031; A-LEN vs A-NEN group, P = 0.017). This was supported by the demonstration of the accumulation of red-tinged fluid in the tracheal tube, and the examination of the BALF protein concentration. Results shown in Figure 4B indicate that a significantly higher LPI was associated with the A-NEL and A-NEN groups (3.8 ± 0.5; 4.2 ± 0.3) as compared with the A-LEN group (3.1 ± 0.6) (A-LEN vs A-NEL, P = 0.011; A-LEN vs A-NEN group, P < 0.001).
Pathological Comparisons
Representative electron microphotographs of rat lungs in the A-LEN (Fig. 5, A and B) and A-NEL (Fig. 5, C and D) groups demonstrated that deformed red blood cells were deposited in the alveolar capillary spaces. Red blood cells and plasma exudation can be seen in the alveolar spaces (Fig. 5A ). Necrosis and desquamation of the pulmonary capillary endothelial cells along the basement membrane and interstitial space are identified, and lipid particles can be seen in interstitial space (Fig. 5B) . In the A-LEN group, the cell nuclei of alveolar type II cells are intact; the mitochondria and lamellar corpuscles have mild cellular edema. Also, the endoplasmic reticulum demonstrates vacuoles (Fig. 5C ). The structure of pulmonary capillary endothelial cells and the basement membrane are intact. There is no plasma exudation in the alveolar spaces (Fig. 5D) . The ultrastructural changes of the A-NEN group are the same as those of the A-NEL group (Fig. 5, E and F) . 17, 18 The A-LEN group exhibited normal pathology/histology. There was no evidence of edema or hemorrhagic necrosis, and the alveolar structure remained unchanged (Fig. 5G ). In the other 2 groups (A-NEL and A-NEN groups), the majority of the alveoli were injured, and their structure was substantially altered; there were numerous erythrocytes associated with the damaged alveolar framework (H, I).
Experiment B
Cardiac tissue and plasma bupivacaine content in the B-LEN group was much lower than that in the other 2 groups (P = 0.001, P = 0.03) (cardiac tissue: B-LEN 7.7 ± 1.2 g/g vs B-NEL 9.3 ± 1.3 g/g; P = 0.001; plasma: B-LEN 13.9 ± 1.1 g/mL vs B-NEL 15.5 ± 1.6 g/mL; P = 0.03).
DISCUSSION
Our bupivacaine-induced model of cardiac depression model showed that the lung W/D ratio and the LPI of the A-LEN group were lower than that of the A-NEL group. The PVP reached a peak (maximum value) within 30 seconds after administration of 10 μg/kg epinephrine and then recovered rapidly in 3 minutes. The A-LEN group had lower PVPs than did the A-NEL and A-NEN groups, thereby demonstrating the importance of giving the lipid emulsion first. However, the PAPs of the 3 groups demonstrated no differences. In experiment B, concentrations of bupivacaine in the cardiac tissue and the plasma of the B-LEN group were lower than those of the B-NEL group. This study demonstrated that prioritizing lipid administration (before epinephrine administration) decreases the PVP and limits the lung injury caused by epinephrine in bupivacaine-induced cardiac arrest/ depression. In this rat model of bupivacaine-induced cardiac depression, we used 15 mg/kg bupivacaine to induce toxicity, which is lower than that in the previous experiments. 19 The physiological aim of our model was to cause cardiac depression (RPP value is reduced to 30% of baseline) rather than cardiac arrest with the infusion of bupivacaine. The epinephrine dosing of 10 μg/kg epinephrine used in our study was taken from the work of Li et al. 20 The mechanisms of pulmonary edema caused by epinephrine may vary among experimental models. Krishnamoorthy found that epinephrine caused an increase in pulmonary blood flow that elevated the pulmonary capillary pressures in the isolated lung. When the pulmonary capillary pressure exceeded the threshold value, pulmonary edema ensued. McCaul et al 7 reported that epinephrine administration was associated with impaired left ventricular diastolic function, early transient left atrial hypertension, and reduced compliance of the left ventricle in "brief " cardiac arrest from asphyxia. We discounted the impact of volume on our experimental results because our A-NEN group received an equal volume of normal saline. This study showed that administration of epinephrine prior to a lipid emulsion created a higher perfusion pressure in the left atrium that led to a depression of cardiac diastolic function and left ventricular compliance.
This study further demonstrated that epinephrine increased the PVP in bupivacaine-induced cardiac depression and resulted in injury. Pulmonary venous pressure is equal to left atrium pressure, thus reflecting left ventricular end-diastolic pressure. 7 The administration of epinephrine increased the left ventricular enddiastolic pressure with a resultant impaired left ventricular compliance, 7 which led to the accumulation of blood in the pulmonary capillaries, resulting in an increased pulmonary capillary pressure (to >12 cm H 2 O) that promoted pulmonary edema, damage to the capillary bed, and alveolar bleeding. However, we documented no changes in PAPs across the 3 groups.
In the second part of our study (experiment B), the group that received the lipid emulsion as the first infusion in resuscitation (B-LEN) was found to have a lower cardiac tissue bupivacaine content, which was consistent with the research of Weinberg et al 22, 23 and supported the "lipid sink" mechanism. Butterworth et al 24 reported that in the presence bupivacaine toxicity even large doses of epinephrine cannot stimulate higher amounts of cyclic adenosine monophosphate. Recently, Fettiplace et al 25 confirmed that lipid emulsion exerts rapid, positive inotropic, and lusitropic effects in both intact and isolated animal heart models. In addition, fatty acid oxidation and calcium homeostasis are involved in the rescue of bupivacaine-induced cardiotoxicity by lipid emulsion in rats. 26 Therefore, the mechanism of lipid emulsion to reduce lung injury induced by epinephrine may be multifaceted.
Our investigation has several limitations. First, the cardiac depression model used in this study cannot absolutely reflect the condition of cardiac arrest induced by bupivacaine in clinical scenarios. Second, although appropriate clinical precautions were taken after thoracotomy to ensure the best simulation of a true clinical environment, such as fluid volume expansion, intraoperative use of bone wax, electrocautery and strict hemostasis, appropriate changes in tidal volume, and maintenance of body temperature, alterations may have occurred to the rats' physiology and affected our results. Finally, the use of chloral hydrate and sevoflurane may have been confounding factors that interfered with the experimental results.
In conclusion, prioritizing the administration of lipid (before epinephrine) during cardiac depression in the case of local anesthetic toxicity may reduce myocardial bupivacaine concentration and relieve left ventricular diastolic dysfunction. Such an action may also decrease the incidence of pulmonary hemorrhage after resuscitation and increase survival. The optimal timing of the administration of a lipid emulsion and its superior effect, if given as the initial therapeutic agent as demonstrated in the present study, may further augment the guidelines for the management of severe local anesthetic toxicity. Furthermore, studies involving an optimal recovery plan for the treatment of local anesthetic toxicity (bupivacaine) using the human model should be explored.
